Search clinical trials for: Darolutamide(Nubeqa, BAY1841788)

Total 82 results

Bayer

Active, not recruiting

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL)

Prostate Cancer

United States, Canada, Japan, Spain, Germany, Belgium, Argentina, Austria, Brazil, Greece, Italy, Russian Federation, Taiwan, China, Denmark, France, Colombia
Bayer

Terminated

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) (DaroAcT)

Prostatic Cancer, Castration-Resistant

United States
Bayer

Recruiting

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Cancer

Korea, Republic of, Spain, United States, China, Australia, Austria, Belgium, Brazil, Colombia, Czechia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Netherlands, Peru, Poland, Portugal, Romania, Russian... and more
Bayer
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

Prostate Cancer Non-Metastatic | Castration-Resistant

Belgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
Bayer

Completed

An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings (DEAR)

Non-metastatic Castration-resistant Prostate Cancer

United States
Bayer

Not yet recruiting

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Non-metastatic Castration-resistant Prostate Cancer | Metastatic Hormone-sensitive Prostate Cancer

Korea, Republic of
Bayer

Recruiting

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Non-metastatic Castration-resistant Prostate Cancer

India
Bayer

Active, not recruiting

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (ARASEC)

Metastatic Hormone-sensitive Prostate Cancer

United States
Bayer

Recruiting

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Biochemically Recurrent Prostate Cancer

Austria, Spain, United States, France, Germany, Taiwan, Denmark, China, Netherlands, Portugal, Japan, Australia, Canada, Hungary, Italy, Finland, United Kingdom, Brazil, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
Bayer

Recruiting

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide (ARAMON)

Biochemically Recurrent Prostate Cancer

United States
Bayer

Active, not recruiting

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Prostate Cancer

United States
Bayer

Completed

An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States (ARENA)

Non-metastatic Prostate Cancer | Non-metastatic Castration-resistant Prostate Cancer

United States
D'Or Institute for Research and Education
Bayer; RPH Central Pharma

Recruiting

A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer

Prostate Cancer

Brazil
GenesisCare USA
Bayer

Withdrawn

Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC (CARE)

Metastatic Prostate Cancer
Bayer

Completed

Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.

Cerebrovascular Circulation

United Kingdom
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Canada
Bayer

Active, not recruiting

An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings (DEAR-EXT)

Non-metastatic Castration-resistant Prostate Cancer

United States
AstraZeneca

Recruiting

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN)

Prostate Cancer

United States, Spain, United Kingdom, Netherlands, Canada, Australia
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital...

Recruiting

Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer

Prostate Cancer

China
Bayer
Orion Corporation, Orion Pharma

Active, not recruiting

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE)

Prostatic Neoplasms

China, Russian Federation, Taiwan, Latvia, India, Australia, Brazil, Canada, Chile, Lithuania, New Zealand, Peru, South Africa, Spain, Ukraine
Trans Tasman Radiation Oncology Group
Bayer; Peter MacCallum Cancer Centre, Australia

Recruiting

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (DECREASE)

Advanced Prostate Carcinoma | Castrate Resistant Prostate Cancer | Cancer of Prostate | PSA

Australia, Singapore
University Health Network, Toronto
Bayer; Prostate Cancer Canada

Not yet recruiting

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer (SChLAP/IDC)

Prostate Cancer

Canada
Alliance Foundation Trials, LLC.
Bayer

Recruiting

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)

Prostate Cancer | Metastatic Prostate Cancer | Prostate Cancer Metastatic | Castrate Resistant Prostate Cancer

United States
MANA RBM
Bayer; Tulane University; Barbara Ann Karmanos Cancer Institute; Carolina Urologic...

Terminated

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE)

Metastatic Castration-resistant Prostate Cancer

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Recruiting

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Prostate Cancer | Prostate Adenocarcinoma | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

United States
Bayer

Active, not recruiting

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States, United Kingdom, Finland
Celcuity Inc

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Genital Diseases, Male | Prostatic Disease | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Urogenital Diseases, Male

United States, France, Spain, United Kingdom
Bayer
Orion Corporation, Orion Pharma

Completed

Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)

Hepatic Insufficiency | Renal Insufficiency | Pharmacokinetics

Germany
UNICANCER
Bayer

Not yet recruiting

Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging (PEACE8)

Prostatic Cancer, Castration-Resistant
UNICANCER
Bayer

Recruiting

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Prostate Cancer Metastatic

Spain, France, Ireland, Belgium
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Metastatic Prostate Cancer | Intermitent Anti-androgen Therapy

China
Association Pour La Recherche des Thérapeutiques...
Bayer

Recruiting

Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases (ALADDIN)

Prostate Cancer

France
Cancer Research Antwerp
Bayer; Veracyte, Inc.

Recruiting

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER)

Prostate Cancer

Belgium
Peking University First Hospital
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaborators

Recruiting

A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer

Prostate Cancer

China
Institut Claudius Regaud
Bayer

Recruiting

SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer (SUGAR)

Prostate Cancer

France
AstraZeneca
Bayer

Recruiting

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Metastatic Prostate Cancer

Italy, United Kingdom, Australia, United States
Latin American Cooperative Oncology Group
Bayer

Active, not recruiting

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) (ExBAT)

Prostate Cancer

Brazil
Bayer
Orion Corporation, Orion Pharma

Completed

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (ARASENS)

Metastatic Hormone-sensitive Prostate Cancer

Belgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
University Hospital, Ghent

Recruiting

Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer (DART)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis

Belgium
Translational Research in Oncology
Bayer

Completed

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Breast Cancer Female

Germany, Canada, United States
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Turkey, Sw...
Eli Lilly and Company
Bayer

Active, not recruiting

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Prostatic Neoplasms

Spain, Germany, United States
Praful Ravi, MB BCHir, MRCP
Eli Lilly and Company; Bayer

Active, not recruiting

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Non-metastatic Prostate Cancer

United States
National Cancer Center Hospital East
Bayer Yakuhin, Ltd.

Active, not recruiting

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Salivary Gland Cancer

Japan
Bayer
Orion Corporation, Orion Pharma

Completed

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers

Prostatic Neoplasms

Germany
Institut Bergonié
Bayer

Recruiting

Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer (DARIUS)

Prostate Cancer

France
Medical University of Vienna

Completed

Clinical Experience With Numeta in Preterm Infants (Numeta)

Premature Infants

Austria
Mamta Parikh
National Cancer Institute (NCI)

Recruiting

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Advanced Prostate Adenocarcinoma

United States
UNICANCER

Completed

Study on Androgen Receptor and Triple Negative Breast Cancer (START)

Breast Cancer Female | Triple Negative and Androgen Receptor Positive

France
St Vincent's Hospital, Sydney

Recruiting

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (PICASSO)

Metastatic Prostate Cancer

Australia

Search clinical trials for: Darolutamide(Nubeqa, BAY1841788)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations